150 related articles for article (PubMed ID: 17221181)
1. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia.
Sabes-Figuera R; Segú JL; Puig-Junoy J; Torres A
Eur J Health Econ; 2008 Feb; 9(1):23-32. PubMed ID: 17221181
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
[TBL] [Abstract][Full Text] [Related]
5. [Short course antibiotherapies in community-acquired pneumonia].
Bulbul Y; Ozlu T
Tuberk Toraks; 2008; 56(3):344-52. PubMed ID: 18932039
[TBL] [Abstract][Full Text] [Related]
6. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Simoens S
Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
[TBL] [Abstract][Full Text] [Related]
7. Community-acquired pneumonia: is it time to shorten the antibiotic treatment?
Esposito S; Fiore M
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community -acquired pneumonia in children.
Aurangzeb B; Hameed A
J Coll Physicians Surg Pak; 2003 Dec; 13(12):704-7. PubMed ID: 15569557
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis of ambulatory treatment for adult patients with community-acquired pneumonia: according to Japanese Respiratory Society guidelines].
Morimoto T; Koyama H; Shimbo T; Fukui T
Nihon Kokyuki Gakkai Zasshi; 2002 Jan; 40(1):17-25. PubMed ID: 11925912
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of resistance in the community.
Eandi M; Zara GP
Int J Clin Pract Suppl; 1998 Jun; 95():27-38. PubMed ID: 9796553
[TBL] [Abstract][Full Text] [Related]
12. Impact of guidelines on outcome: the evidence.
Martínez R; Reyes S; Lorenzo MJ; Menéndez R
Semin Respir Crit Care Med; 2009 Apr; 30(2):172-8. PubMed ID: 19296417
[TBL] [Abstract][Full Text] [Related]
13. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia.
Opmeer BC; El Moussaoui R; Bossuyt PM; Speelman P; Prins JM; de Borgie CA
J Antimicrob Chemother; 2007 Nov; 60(5):1131-6. PubMed ID: 17827142
[TBL] [Abstract][Full Text] [Related]
14. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
15. [Reducing the duration of antibiotic therapy in acute community-acquired pneumonia].
Groupe Entretiens du Club de réflexion sur l'infection respiratoire
Rev Pneumol Clin; 2008 Feb; 64(1):3-7. PubMed ID: 18603172
[TBL] [Abstract][Full Text] [Related]
16. Cost of antibiotic therapy for community-acquired pneumonia.
Trevisani L; Putinati S; Sartori S; Potena A
Eur J Med; 1992 Oct; 1(6):380-1. PubMed ID: 1341474
[No Abstract] [Full Text] [Related]
17. Costs of treating lower respiratory tract infections.
Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
Bhavnani SM; Ambrose PG
Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
[TBL] [Abstract][Full Text] [Related]
19. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia.
Daneman N; Low DE; McGeer A; Green KA; Fisman DN
Clin Infect Dis; 2008 Apr; 46(8):1131-8. PubMed ID: 18444846
[TBL] [Abstract][Full Text] [Related]
20. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
Starodubtseva OI; Vakhrushev IaM
Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
